IRONWOOD PHARMACEUTICALS, INC. Retained Earnings
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Retained Earnings of -$1.58 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.58B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.63B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.67B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.67B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.58B 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$1.63B 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$1.67B 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$1.67B 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$1.71B 10-Q · filed 2025-08-11 |
| 2025-03-31 | -$1.74B 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$1.70B 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.70B 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$1.70B 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$1.70B 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$1.70B 10-K · filed 2025-03-31 |
| 2023-09-30 | -$1.70B 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$1.71B 10-Q · filed 2023-08-09 |
| 2023-03-31 | -$650.66M 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$696.38M 10-K · filed 2024-02-16 |
| 2022-09-30 | -$745.24M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$795.56M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$832.64M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$937.61M 10-K · filed 2025-03-31 |
| 2021-09-30 | -$978.98M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$1.03B 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$1.43B 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$1.47B 10-K · filed 2022-02-18 |
| 2020-09-30 | -$1.51B 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$1.54B 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$1.57B 10-Q · filed 2020-05-06 |
| 2019-12-31 | -$1.57B 10-K · filed 2021-02-17 |
| 2019-09-30 | -$1.62B 10-Q · filed 2019-10-31 |
| 2019-06-30 | -$1.64B 10-Q · filed 2019-07-30 |
| 2019-03-31 | -$1.65B 10-Q · filed 2019-05-02 |
| 2018-12-31 | -$1.59B 10-K · filed 2020-02-13 |
| 2018-09-30 | -$1.58B 10-Q · filed 2018-11-06 |
| 2018-06-30 | -$1.40B 10-Q · filed 2018-08-06 |
| 2018-03-31 | -$1.35B 10-Q · filed 2018-05-04 |
| 2017-12-31 | -$1.31B 10-K · filed 2019-02-25 |
| 2017-09-30 | -$1.32B 10-Q · filed 2017-11-02 |
| 2017-06-30 | -$1.29B 10-Q · filed 2017-08-03 |
| 2017-03-31 | -$1.24B 10-Q · filed 2017-05-08 |
| 2016-12-31 | -$1.19B 10-K · filed 2018-02-22 |
| 2016-09-30 | -$1.18B 10-Q · filed 2016-11-07 |
| 2016-06-30 | -$1.15B 10-Q · filed 2016-08-08 |
| 2016-03-31 | -$1.12B 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$1.11B 10-K · filed 2017-02-22 |
| 2015-09-30 | -$1.10B 10-Q · filed 2015-11-05 |
| 2015-06-30 | -$1.05B 10-Q · filed 2015-08-07 |
| 2015-03-31 | -$1.00B 10-Q · filed 2015-05-06 |
| 2014-12-31 | -$967.45M 10-K · filed 2016-02-19 |
| 2014-09-30 | -$929.80M 10-Q · filed 2014-11-05 |
| 2014-06-30 | -$887.81M 10-Q · filed 2014-08-05 |
| 2014-03-31 | -$827.45M 10-Q · filed 2014-04-29 |
| 2013-12-31 | -$777.83M 10-K · filed 2015-02-18 |
| 2013-09-30 | -$725.84M 10-Q · filed 2013-10-28 |
| 2013-06-30 | -$664.07M 10-Q · filed 2013-08-08 |
| 2013-03-31 | -$598.92M 10-Q · filed 2013-04-23 |
| 2012-12-31 | -$505.02M 10-K · filed 2014-02-07 |
| 2012-09-30 | -$461.16M 10-Q · filed 2012-11-06 |
| 2012-06-30 | -$508.80M 10-Q · filed 2012-08-07 |
| 2012-03-31 | -$467.99M 10-Q · filed 2012-05-10 |
| 2011-12-31 | -$432.39M 10-K · filed 2013-02-21 |
| 2011-09-30 | -$425.42M 10-Q · filed 2011-11-09 |
| 2011-06-30 | -$404.79M 10-Q · filed 2011-08-12 |
| 2010-12-31 | -$367.54M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |